Form 8-K - Current report:
SEC Accession No. 0001640334-17-000329
Filing Date
2017-02-17
Accepted
2017-02-17 15:18:58
Documents
3
Period of Report
2017-02-15
Items
Item 4.01: Changes in Registrant's Certifying Accountant
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K newgen_8k.htm 8-K 14832
2 LETTER OF KLJ & ASSOCIATES, LLP. newgen_ex161.htm EX-16.1 2016
3 newgen_ex161img1.jpg GRAPHIC 7431
  Complete submission text file 0001640334-17-000329.txt   28429
Mailing Address 506 2ND AVENUE, SUITE 1400 SEATTLE WA 98104
Business Address 506 2ND AVENUE, SUITE 1400 SEATTLE WA 98104 855-624-4973
NewGen BioPharma Corp. (Filer) CIK: 0001537274 (see all company filings)

EIN.: 680679973 | State of Incorp.: NV | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 333-178741 | Film No.: 17621130
SIC: 3612 Power, Distribution & Specialty Transformers